Aquestive Therapeutics (NASDAQ:AQST) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST - Free Report) in a research note released on Wednesday, Benzinga reports. The firm currently has a $10.00 price objective on the stock.

A number of other research analysts have also weighed in on the stock. Leerink Partners raised their target price on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a report on Friday, October 25th. JMP Securities reissued a "market outperform" rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $8.83.

Aquestive Therapeutics Trading Up 8.6 %

Shares of NASDAQ:AQST traded up $0.41 during midday trading on Wednesday, reaching $5.17. 1,511,951 shares of the company were exchanged, compared to its average volume of 1,752,992. The stock has a market cap of $470.78 million, a PE ratio of -11.00 and a beta of 2.82. The business's fifty day moving average is $4.90 and its two-hundred day moving average is $3.82. Aquestive Therapeutics has a one year low of $1.55 and a one year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to analysts' expectations of $12.69 million. During the same period last year, the firm posted ($0.03) EPS. As a group, sell-side analysts expect that Aquestive Therapeutics will post -0.48 EPS for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Financial Advocates Investment Management increased its stake in Aquestive Therapeutics by 14.7% during the 3rd quarter. Financial Advocates Investment Management now owns 39,000 shares of the company's stock worth $194,000 after buying an additional 5,000 shares during the period. nVerses Capital LLC purchased a new position in shares of Aquestive Therapeutics during the third quarter worth about $28,000. SG Americas Securities LLC increased its position in Aquestive Therapeutics by 58.9% during the third quarter. SG Americas Securities LLC now owns 25,619 shares of the company's stock worth $128,000 after buying an additional 9,496 shares during the period. Victory Capital Management Inc. purchased a new stake in Aquestive Therapeutics in the 2nd quarter valued at $27,000. Finally, PFG Investments LLC boosted its stake in shares of Aquestive Therapeutics by 22.9% during the second quarter. PFG Investments LLC now owns 59,000 shares of the company's stock worth $153,000 after buying an additional 11,000 shares during the period. Institutional investors and hedge funds own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.